JFO Open Ophthalmology最新文献

英文中文

Efficacy and safety of intracameral epinephrine as mydriatic agent in cataract surgery: A systematic review 巩膜内肾上腺素在白内障手术中的有效性和安全性：一项系统综述

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2025-05-17 DOI: 10.1016/j.jfop.2025.100169

Fahad Butt , Mohamad Tarek Madani , Salem Abu Al-Burak , Thanansayan Dhivagaran , Brendan K. Tao , Amit Garg , Cindy Hutnik , Monali S. Malvankar-Mehta

Purpose

To evaluate the efficacy, safety, and cost implications of using epinephrine (Epi) as an additive in balanced salt solution (BSS) during cataract surgery, focusing on intraoperative pupil dilation, side effects, and cost considerations.

Methods

Searches were conducted across multiple databases, including EMBASE, MEDLINE, CINAHL, and Web of Science, up to October 17, 2024. Eligibility criteria included studies assessing intracameral epinephrine for achieving or maintaining mydriasis, and reporting outcomes related to efficacy, adverse effects, intraoperative complications, and cost implications.

Results

Of the 476 articles screened, 23 met the inclusion criteria, involving 4262 cataract surgeries were included. Intracameral epinephrine consistently maintained pupil dilation, with reported average pupil sizes ranging from 6.9 mm to 7.2 mm, significantly reducing the need for additional mechanical dilation interventions (reported incidence <1% in some studies). Its use reduced the incidence of intraoperative floppy iris syndrome (IFIS) in high-risk patients. It minimized complications such as posterior capsular rupture and iris prolapse. Combination therapy with adjunctive agents like NSAIDs or lidocaine further improved dilation stability and reduced intraoperative miosis. Safety data revealed no significant impact on heart rate or blood pressure, demonstrating hemodynamic stability. Cost analyses highlighted savings from reduced surgical times (i.e., ∼13.5 min vs. ∼17.2 min with epinephrine alone) and decreased use of pupil expansion devices, resulting in estimated savings of over $19,000 in high-volume centers.

Conclusion

Intracameral epinephrine effectively supports stable pupil dilation and reduces intraoperative complications in cataract surgery. It offers a safe and cost-effective alternative to traditional mydriatic agents, particularly when combined with adjunctive medications. However, given the considerable advancements in surgical techniques over time, caution should be exercised when interpreting findings from earlier studies. Additionally, the cost of epinephrine preparation, alongside its potential endothelial toxicity at higher concentrations, highlights the need for further research into the feasibility of using BSS without epinephrine in routine practice.

目的评价在白内障手术中使用肾上腺素（Epi）作为平衡盐溶液（BSS）添加剂的疗效、安全性和成本影响，重点关注术中瞳孔扩张、副作用和成本考虑。方法检索截止到2024年10月17日的多个数据库，包括EMBASE、MEDLINE、CINAHL和Web of Science。入选标准包括评估肠胃膜内肾上腺素用于实现或维持滴虫病的研究，并报告与疗效、不良反应、术中并发症和成本相关的结果。结果476篇文献中，23篇符合纳入标准，共纳入4262例白内障手术。内窥镜肾上腺素持续维持瞳孔扩张，报道的平均瞳孔大小在6.9 mm至7.2 mm之间，显著减少了额外机械扩张干预的需要（在一些研究中报道的发生率为1%）。它的使用降低了高危患者术中虹膜松弛综合征（IFIS）的发生率。它减少并发症，如后囊膜破裂和虹膜脱垂。与非甾体抗炎药或利多卡因等辅助药物联合治疗可进一步改善舒张稳定性并减少术中缩小。安全性数据显示对心率或血压无显著影响，表明血流动力学稳定。成本分析强调了减少手术时间（即，与单独使用肾上腺素的17.2分钟相比，减少手术时间为13.5分钟）和减少瞳孔扩张装置的使用所节省的费用，估计在大容量中心节省了超过19,000美元。结论膜内肾上腺素能有效地支持白内障手术中稳定的瞳孔扩张，减少术中并发症。它提供了一种安全且具有成本效益的替代传统药物，特别是当与辅助药物联合使用时。然而，随着时间的推移，鉴于手术技术的长足进步，在解释早期研究的结果时应谨慎行事。此外，肾上腺素制备的成本，以及其在高浓度下潜在的内皮毒性，表明需要进一步研究在常规实践中使用不含肾上腺素的BSS的可行性。

{"title":"Efficacy and safety of intracameral epinephrine as mydriatic agent in cataract surgery: A systematic review","authors":"Fahad Butt , Mohamad Tarek Madani , Salem Abu Al-Burak , Thanansayan Dhivagaran , Brendan K. Tao , Amit Garg , Cindy Hutnik , Monali S. Malvankar-Mehta","doi":"10.1016/j.jfop.2025.100169","DOIUrl":"10.1016/j.jfop.2025.100169","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the efficacy, safety, and cost implications of using epinephrine (Epi) as an additive in balanced salt solution (BSS) during cataract surgery, focusing on intraoperative pupil dilation, side effects, and cost considerations.</div></div><div><h3>Methods</h3><div>Searches were conducted across multiple databases, including EMBASE, MEDLINE, CINAHL, and Web of Science, up to October 17, 2024. Eligibility criteria included studies assessing intracameral epinephrine for achieving or maintaining mydriasis, and reporting outcomes related to efficacy, adverse effects, intraoperative complications, and cost implications.</div></div><div><h3>Results</h3><div>Of the 476 articles screened, 23 met the inclusion criteria, involving 4262 cataract surgeries were included. Intracameral epinephrine consistently maintained pupil dilation, with reported average pupil sizes ranging from 6.9 mm to 7.2 mm, significantly reducing the need for additional mechanical dilation interventions (reported incidence <1% in some studies). Its use reduced the incidence of intraoperative floppy iris syndrome (IFIS) in high-risk patients. It minimized complications such as posterior capsular rupture and iris prolapse. Combination therapy with adjunctive agents like NSAIDs or lidocaine further improved dilation stability and reduced intraoperative miosis. Safety data revealed no significant impact on heart rate or blood pressure, demonstrating hemodynamic stability. Cost analyses highlighted savings from reduced surgical times (i.e., ∼13.5 min vs. ∼17.2 min with epinephrine alone) and decreased use of pupil expansion devices, resulting in estimated savings of over $19,000 in high-volume centers.</div></div><div><h3>Conclusion</h3><div>Intracameral epinephrine effectively supports stable pupil dilation and reduces intraoperative complications in cataract surgery. It offers a safe and cost-effective alternative to traditional mydriatic agents, particularly when combined with adjunctive medications. However, given the considerable advancements in surgical techniques over time, caution should be exercised when interpreting findings from earlier studies. Additionally, the cost of epinephrine preparation, alongside its potential endothelial toxicity at higher concentrations, highlights the need for further research into the feasibility of using BSS without epinephrine in routine practice.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"11 ","pages":"Article 100169"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of dual ocular toxocariasis in an adult 成人双眼弓形虫病1例

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2025-07-17 DOI: 10.1016/j.jfop.2025.100179

Taoufik Abdellaoui , Adil Bouzidi , Said Iferkhass , Aziz EL Ouafi

引用次数: 0

Topographic, pachymetric and epithelial thickness distribution patterns in clinically unaffected fellow eyes of patients with asymmetric keratoconus 不对称圆锥角膜患者临床未受影响的眼的地形、厚度和上皮厚度分布模式

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2024-08-22 DOI: 10.1016/j.jfop.2024.100126

Rajneesh Dhiman, Barkha Gupta, Arun Kumar Jain, Amit Gup, Jagat Ram, Chintan Malhotra

Purpose

To compare topographic, pachymetric and epithelial distribution patterns of clinically unaffected fellow eyes of patients with asymmetric keratoconus (AKC) with those of normal controls and keratoconic fellow eyes.

Methods

A prospective, observational study was conducted at a tertiary care center, in which twenty-five clinically unaffected fellow eyes in patients with AKC were compared to 25 keratoconic fellow eyes and 67 normal controls. Pachymetric and epithelial thicknesses in the central 2 mm and 8 octants in the 2–5 mm and 5–7 mm zones were compared using Spectral Domain Optical Coherence Tomography (SDOCT). Scheimpflug derived topography was also compared.

Results

Mean simulated keratometry of fellow eyes (43.6D ± 1.34 D) was comparable to that of control eyes (43.85D ± 1.57 D) (p > 0.99) and less than that of keratoconic eyes (47.08D ± 4.62 D) (p = 0.004). Central corneal and epithelial thicknesses of fellow eyes (474.28 ± 40.27 μm, 52.76 ± 7.45 μm, respectively) were less than in control eyes (505.97 ± 30.12 μm, 60.48 ± 8.37 μm) (p < 0.001 and p = 0.006, respectively) but comparable to those of keratoconic eyes (470.48 ± 44.19 μm, 52.48 ± 8.00 μm) (p > 0.99). Pachymetric differences of radially opposite octants in the 2–5 mm zone demonstrated thinning in the inferior and inferotemporal octants of fellow eyes which was greater than that seen in control eyes (p = 0.017 and 0.04, respectively)

Conclusion

Reduced central epithelial thickness and greater pachymetric differences in radially opposite octants of the mid-peripheral cornea may be suggestive of susceptibility to ectasia despite normal topography.

目的比较不对称圆锥角膜（AKC）患者与正常对照及圆锥角膜患者的眼的地形、厚度及上皮分布特征。方法在一家三级保健中心进行了一项前瞻性观察性研究，其中25只临床未受影响的AKC患者与25只角膜移植患者和67只正常对照进行了比较。使用光谱域光学相干断层扫描（SDOCT）比较中央2 mm和2 - 5 mm和5-7 mm区域8八分位的厚层和上皮厚度。还比较了Scheimpflug衍生地形。结果同组眼的平均模拟角膜测量值（436 D±1.34 D）与对照组（43.85D±1.57 D）相当（p > 0.99），低于角膜移植组（47.08D±4.62 D）（p = 0.004）。观察组角膜中央和上皮厚度（分别为474.28±40.27 μm, 52.76±7.45 μm）小于对照组（505.97±30.12 μm, 60.48±8.37 μm）（p <； 0.001和p = 0.006），但与角膜植入组（470.48±44.19 μm, 52.48±8.00 μm）相当（p > 0.99）。2-5 mm区径向对侧八分区厚度差异表明，同侧眼的下、颞下八分区厚度变薄，差异大于对照组（p分别为0.017和0.04）。结论中周周角膜径向对侧八分区中心上皮厚度减小和厚度差异增大可能提示角膜中周周角膜在正常地形下易发生扩张。

{"title":"Topographic, pachymetric and epithelial thickness distribution patterns in clinically unaffected fellow eyes of patients with asymmetric keratoconus","authors":"Rajneesh Dhiman, Barkha Gupta, Arun Kumar Jain, Amit Gup, Jagat Ram, Chintan Malhotra","doi":"10.1016/j.jfop.2024.100126","DOIUrl":"10.1016/j.jfop.2024.100126","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare topographic, pachymetric and epithelial distribution patterns of clinically unaffected fellow eyes of patients with asymmetric keratoconus (AKC) with those of normal controls and keratoconic fellow eyes.</div></div><div><h3>Methods</h3><div>A prospective, observational study was conducted at a tertiary care center, in which twenty-five clinically unaffected fellow eyes in patients with AKC were compared to 25 keratoconic fellow eyes and 67 normal controls. Pachymetric and epithelial thicknesses in the central 2 mm and 8 octants in the 2–5 mm and 5–7 mm zones were compared using Spectral Domain Optical Coherence Tomography (SDOCT). Scheimpflug derived topography was also compared.</div></div><div><h3>Results</h3><div>Mean simulated keratometry of fellow eyes (43.6D ± 1.34 D) was comparable to that of control eyes (43.85D ± 1.57 D) (p > 0.99) and less than that of keratoconic eyes (47.08D ± 4.62 D) (p = 0.004). Central corneal and epithelial thicknesses of fellow eyes (474.28 ± 40.27 μm, 52.76 ± 7.45 μm, respectively) were less than in control eyes (505.97 ± 30.12 μm, 60.48 ± 8.37 μm) (p < 0.001 and p = 0.006, respectively) but comparable to those of keratoconic eyes (470.48 ± 44.19 μm, 52.48 ± 8.00 μm) (p > 0.99). Pachymetric differences of radially opposite octants in the 2–5 mm zone demonstrated thinning in the inferior and inferotemporal octants of fellow eyes which was greater than that seen in control eyes (p = 0.017 and 0.04, respectively)</div></div><div><h3>Conclusion</h3><div>Reduced central epithelial thickness and greater pachymetric differences in radially opposite octants of the mid-peripheral cornea may be suggestive of susceptibility to ectasia despite normal topography.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"11 ","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of willingness to accept glaucoma surgery among glaucoma patients at a quaternary hospital in Ghana 加纳一家第四医院青光眼患者接受青光眼手术意愿的预测因素

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2025-06-13 DOI: 10.1016/j.jfop.2025.100177

Samuel Ira Kuma , Yaw Akye Essuman , Benjamin Abaidoo , Vera Adobea Essuman , Mildred Johnson , Naa Naamuah Tagoe

Purpose

Glaucoma, an optic neuropathy and major cause of avoidable irreversible blindness worldwide, has public health implications for the quality of life of affected individuals. Surgery is usually indicated when medical treatments fail or as primary treatment in severe disease. Anecdotally, willingness to accept glaucoma surgery among patients at the Lions International Eye Centre (LIEC), Korle Bu Teaching Hospital (KBTH) is low. This study thus sought to determine the predictors of willingness to accept glaucoma surgery among glaucoma patients at the LIEC, KBTH.

Materials and methods

This was a cross-sectional, hospital-based study among adult patients with glaucoma at the LIEC, KBTH from July 2022 to February 2024. Data were analyzed using SPSS version 26. Descriptive and inferential statistics were performed on the data. P-values <0.05 were considered statistically significant.

Results

We included 240 participants, consisting of 122 (50.8%) females and 118 (49.2%) males.

The majority (180, 75.0%) were aged ≥ 48 years. Ninety-eight (40.8%) had lived with glaucoma for ≥ 5 years. Most participants (149, 62.1%) were willing to accept surgery as a treatment option. Fear of surgery (53, 22.1%) and blindness (50, 20.8%) were reasons provided for non-acceptance of surgery. Educational level, residential area, and family history of glaucoma were associated with knowledge about glaucoma (p < 0.05). Male gender (AOR = 2.0; CI = 1.0−3.3; p = 0.036) and presence of comorbidities (AOR = 0.4; CI = 0.2−0.7; p = 0.002) were predictors of willingness to accept glaucoma surgery.

Conclusions

Most glaucoma patients at the Korle Bu Teaching Hospital were willing to accept glaucoma surgery. Male gender and presence of comorbidities predicted willingness to accept glaucoma surgery. Consequently, there is a need for increased education on the necessity of glaucoma surgery.

青光眼是一种视神经病变，是世界范围内可避免的不可逆失明的主要原因，对患者的生活质量具有公共卫生影响。当药物治疗失败或作为严重疾病的主要治疗时，通常需要进行手术。有趣的是，狮子会国际眼科中心（LIEC） Korle Bu教学医院（KBTH）的患者接受青光眼手术的意愿很低。因此，本研究旨在确定LIEC， KBTH青光眼患者接受青光眼手术意愿的预测因素。材料和方法这是一项横断面的、以医院为基础的研究，研究对象是2022年7月至2024年2月在LIEC， KBTH的成年青光眼患者。数据分析采用SPSS version 26。对数据进行描述性和推断性统计。p值<；0.05认为有统计学意义。结果共纳入受试者240例，其中女性122例（50.8%），男性118例（49.2%）。大多数（180例，75.0%）年龄≥48岁。98例（40.8%）患者青光眼≥5年。大多数参与者（149人，62.1%）愿意接受手术作为治疗选择。害怕手术（53,22.1%）和失明（50,20.8%）是不接受手术的原因。受教育程度、居住地区、青光眼家族史与青光眼知识相关(p <；0.05)。男性(AOR = 2.0；Ci = 1.0−3.3；p = 0.036)和合并症的存在(AOR = 0.4；Ci = 0.2 ~ 0.7；P = 0.002)是青光眼手术意愿的预测因子。结论科勒布教学医院青光眼患者多数愿意接受青光眼手术治疗。男性性别和合并症的存在预测了接受青光眼手术的意愿。因此，有必要加强对青光眼手术必要性的教育。

{"title":"Predictors of willingness to accept glaucoma surgery among glaucoma patients at a quaternary hospital in Ghana","authors":"Samuel Ira Kuma , Yaw Akye Essuman , Benjamin Abaidoo , Vera Adobea Essuman , Mildred Johnson , Naa Naamuah Tagoe","doi":"10.1016/j.jfop.2025.100177","DOIUrl":"10.1016/j.jfop.2025.100177","url":null,"abstract":"<div><h3>Purpose</h3><div>Glaucoma, an optic neuropathy and major cause of avoidable irreversible blindness worldwide, has public health implications for the quality of life of affected individuals. Surgery is usually indicated when medical treatments fail or as primary treatment in severe disease. Anecdotally, willingness to accept glaucoma surgery among patients at the Lions International Eye Centre (LIEC), Korle Bu Teaching Hospital (KBTH) is low. This study thus sought to determine the predictors of willingness to accept glaucoma surgery among glaucoma patients at the LIEC, KBTH.</div></div><div><h3>Materials and methods</h3><div>This was a cross-sectional, hospital-based study among adult patients with glaucoma at the LIEC, KBTH from July 2022 to February 2024. Data were analyzed using SPSS version 26. Descriptive and inferential statistics were performed on the data. P-values <0.05 were considered statistically significant.</div></div><div><h3>Results</h3><div>We included 240 participants, consisting of 122 (50.8%) females and 118 (49.2%) males.</div><div>The majority (180, 75.0%) were aged ≥ 48 years. Ninety-eight (40.8%) had lived with glaucoma for ≥ 5 years. Most participants (149, 62.1%) were willing to accept surgery as a treatment option. Fear of surgery (53, 22.1%) and blindness (50, 20.8%) were reasons provided for non-acceptance of surgery. Educational level, residential area, and family history of glaucoma were associated with knowledge about glaucoma (<em>p</em> < 0.05). Male gender (AOR = 2.0; CI = 1.0−3.3; p = 0.036) and presence of comorbidities (AOR = 0.4; CI = 0.2−0.7; p = 0.002) were predictors of willingness to accept glaucoma surgery.</div></div><div><h3>Conclusions</h3><div>Most glaucoma patients at the Korle Bu Teaching Hospital were willing to accept glaucoma surgery. Male gender and presence of comorbidities predicted willingness to accept glaucoma surgery. Consequently, there is a need for increased education on the necessity of glaucoma surgery.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"11 ","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravitreal Stivant® (a biosimilar to bevacizumab) alone versus combined with triamcinolone in center-involved diabetic macular edema 玻璃体内Stivant®（一种贝伐单抗的生物仿制药）单独与曲安奈德联合治疗中心累及性糖尿病黄斑水肿

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2025-05-22 DOI: 10.1016/j.jfop.2025.100173

Arash Daneshtalab , Meysam Shekofteh , Hesam Fat’hi-zadeh , Mohammad Taher Rajabi , Seyed Mohsen Rafizadeh , Amirhossein Aghajani , Shaghayegh Esfandiarifard , Zahra Akbari , Mahsa Sardarinia , Kaveh Jamalipour Soufi , Amin Zand

Purpose

To compare the effects of intravitreal Stivant® (a biosimilar to bevacizumab) alone and in combination with triamcinolone acetonide in center-involved diabetic macular edema (DME).

Methods

In this randomized controlled study, patients with center-involved DME (central macular thickness [CMT] > 300 μm) were assigned to receive either intravitreal Stivant® 1.25 mg alone (IVS group) or in combination with triamcinolone acetonide 1 mg (IVST group). The regimen consisted of injections every 4 weeks, administered three times. Changes in best-corrected visual acuity (BCVA) and CMT from baseline to follow-up visits were compared between the groups.

Results

Of the 140 enrolled participants, 70 eyes of 70 patients were assigned to each group. By week 12, both groups showed improvements in BCVA and CMT compared to baseline values (Ps < 0.001). BCVA (in logarithm of the minimum angle of resolution [logMAR] scale) improved more in the IVST group (0.75 ± 0.62 logMAR) compared to the IVS group (0.92 ± 0.93 logMAR, P < 0.001) at week 4. However, by week 12, BCVA did not differ between the two groups (P = 0.089). Similarly, although the IVST group demonstrated a higher reduction in mean CMT (−143.40 ± 58.28 μm) compared to the IVS group (−92.19 ± 52.31 μm, P < 0.001) at week 4, this effect did not persist at the next follow-up visits.

Conclusion

In eyes with center-involved DME, IVST is more effective in reducing CMT and improving BCVA than IVS up to 1 month, but this superiority does not persist over time.

目的比较玻璃体内注射Stivant®（一种贝伐单抗生物类似药）单用和联合曲安奈德治疗中心累及性糖尿病黄斑水肿（DME）的疗效。方法在本随机对照研究中，中心受病灶DME（中央黄斑厚度[CMT] >； 300 μm）患者分别接受单独1.25 mg玻璃体注射（IVS组）和1 mg曲安奈德（IVST组）。该方案包括每4周注射一次，给药3次。比较两组从基线到随访的最佳矫正视力（BCVA）和CMT的变化。结果在140名参与者中，70名患者的70只眼睛被分配到每组。到第12周，两组患者BCVA和CMT均较基线值有所改善（p < 0.001）。在第4周，IVST组的BCVA（以最小分辨角[logMAR]量表的对数表示）（0.75±0.62 logMAR）比IVS组（0.92±0.93 logMAR, P < 0.001）改善更多。然而，到第12周，两组之间的BCVA没有差异（P = 0.089）。同样，尽管IVST组在第4周的平均CMT（- 143.40±58.28 μm）比IVS组（- 92.19±52.31 μm, P < 0.001）有更高的降低，但这种效果在下一次随访时并不持续。结论对于中心受累DME， IVST在降低CMT和改善BCVA方面比IVS在1个月内更有效，但这种优势并不持续。

{"title":"Intravitreal Stivant® (a biosimilar to bevacizumab) alone versus combined with triamcinolone in center-involved diabetic macular edema","authors":"Arash Daneshtalab , Meysam Shekofteh , Hesam Fat’hi-zadeh , Mohammad Taher Rajabi , Seyed Mohsen Rafizadeh , Amirhossein Aghajani , Shaghayegh Esfandiarifard , Zahra Akbari , Mahsa Sardarinia , Kaveh Jamalipour Soufi , Amin Zand","doi":"10.1016/j.jfop.2025.100173","DOIUrl":"10.1016/j.jfop.2025.100173","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the effects of intravitreal Stivant® (a biosimilar to bevacizumab) alone and in combination with triamcinolone acetonide in center-involved diabetic macular edema (DME).</div></div><div><h3>Methods</h3><div>In this randomized controlled study, patients with center-involved DME (central macular thickness [CMT] > 300 μm) were assigned to receive either intravitreal Stivant® 1.25 mg alone (IVS group) or in combination with triamcinolone acetonide 1 mg (IVST group). The regimen consisted of injections every 4 weeks, administered three times. Changes in best-corrected visual acuity (BCVA) and CMT from baseline to follow-up visits were compared between the groups.</div></div><div><h3>Results</h3><div>Of the 140 enrolled participants, 70 eyes of 70 patients were assigned to each group. By week 12, both groups showed improvements in BCVA and CMT compared to baseline values (<em>P</em>s < 0.001). BCVA (in logarithm of the minimum angle of resolution [logMAR] scale) improved more in the IVST group (0.75 ± 0.62 logMAR) compared to the IVS group (0.92 ± 0.93 logMAR, <em>P</em> < 0.001) at week 4. However, by week 12, BCVA did not differ between the two groups (<em>P</em> = 0.089). Similarly, although the IVST group demonstrated a higher reduction in mean CMT (−143.40 ± 58.28 μm) compared to the IVS group (−92.19 ± 52.31 μm, <em>P</em> < 0.001) at week 4, this effect did not persist at the next follow-up visits.</div></div><div><h3>Conclusion</h3><div>In eyes with center-involved DME, IVST is more effective in reducing CMT and improving BCVA than IVS up to 1 month, but this superiority does not persist over time.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"11 ","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corneal foreign body: Management and clinical simulation training 角膜异物：管理与临床模拟训练

JFO Open Ophthalmology

Pub Date : 2025-09-01 Epub Date: 2025-05-22 DOI: 10.1016/j.jfop.2025.100172

Gilles Terlonge, Allison Gilbert, Alexandre Ghuysen

For patients with eye injuries, especially corneal foreign bodies, care pathways may vary depending on many circumstances. Mild cases can progress rapidly within hours and threaten the functional prognosis. Various clinical practitioners may be consulted for urgent care in this context. Each provider will propose specific care according to their resources and level of specialization. A well-codified management strategy and adequate training of healthcare providers might ensure improved standards of care for patients. Several classification tools for corneal foreign bodies are available. Removal is the mainstay of treatment, and several techniques are described, particularly in cases of metallic foreign bodies. The use of slit-lamp magnification should be considered in most cases. Various clinical simulation models have already been tested. We present herein an original model that takes advantage of affordability and realistic visual and tactile feedback, as well as innovative early recognition of iatrogenic corneal perforation and realistic interference from the upper eyelid.

对于眼睛受伤的患者，特别是角膜异物，护理途径可能根据许多情况而变化。轻者可在数小时内迅速进展并威胁到功能性预后。在这种情况下，可以咨询各种临床医生的紧急护理。每个提供者将根据他们的资源和专业化水平提出具体的护理建议。完善的管理策略和对医疗保健提供者的充分培训可确保提高对患者的护理标准。角膜异物有几种分类工具可用。去除是治疗的主要方法，并介绍了几种技术，特别是在金属异物的情况下。在大多数情况下，应考虑使用狭缝灯放大。各种临床模拟模型已经进行了测试。我们在此提出了一种原始模型，该模型利用了可负担性和逼真的视觉和触觉反馈，以及创新的医源性角膜穿孔早期识别和逼真的上眼睑干扰。

引用次数: 0

Real-life evaluation of the home vision monitoring application Odysight® in primary and secondary prevention of exudative maculopathies 家庭视力监测应用程序奥德莱特®在渗出性黄斑病一级和二级预防中的实际评估

JFO Open Ophthalmology

Pub Date : 2025-06-01 Epub Date: 2025-04-30 DOI: 10.1016/j.jfop.2025.100166

Auberie Bonjean , Mathieu Lehmann , Laura Moyal , Pascale Massin , Bénédicte Dupas

Objective

To assess the performance of the Odysight® self-monitoring tool for primary and secondary prevention of exudative maculopathies.

Methods

A one-year retrospective evaluation was conducted in a private practice. An alert was considered significant (SA) when patient was symptomatic, and non significant (NSA) when the patient was asymptomatic and the VA drop was refuted by an additional test carried out the next day.

Results

Of the 92 patients who received a prescription, 44 (48%) downloaded and used the application and were analyzed. At the end of the year, there were 24 (55.8%) active patients. 29 alerts were generated, 13 were considered as NSA, and no anticipated appointment was given. The remaining 16 alerts were SA, 6 (21%) of them were true positive, i.e, revelealed a disease activity on OCT, leading to anticipated injection (representing 9.3% of the patients). 83% of the true positive alerts were generated by eyes with retinal vein occlusion (RVO). Eleven false negative events occurred (6 (55%) for AMD, 4 (36%) for RVO, 1 (9%) for myopic MNV). No primary exudation occured, although 7 false positive alerts were generated. The overall sensitivity of alerts for detecting OCT recurrence was 35.3% (95% CI [12.6; 58]), specificity was 93% (95% CI [90.3; 95.8]), positive predictive value was 20.7% (95% CI [6; 35.7]), and negative predictive value was 96.5% (95% CI [94.5; 98.6]). Sensitivity was higher for RVO (55.6% (95% CI [26.7; 81.1]) than for AMD (14.3% (95% CI [2.6; 51.3]).

Conclusion

In this real-life experimentation of Odysight, half of the patients used the application after initial prescription. Participation was low among diabetics. Odysight® allowed about 10% of the cohort to receive earlier intravitreal injection, albeit with a high number of false positives. Sensitivity was low in secondary prevention for AMD, and better for patients with RVO. Additional use in primary prevention may be questionable.

目的评价Odysight®自我监测工具在渗出性黄斑病一级和二级预防中的应用效果。方法对某私人执业医师进行为期一年的回顾性评估。当患者有症状时为警报被认为是显著的（SA），当患者无症状时为非显著（NSA），第二天进行的额外测试驳斥了VA下降。结果在92例收到处方的患者中，有44例（48%）下载并使用了该应用程序并进行了分析。年末活跃患者24例（55.8%）。产生了29个警报，13个被认为是国家安全局，没有预期的任命。其余16个警报为SA，其中6个（21%）为真阳性，即在OCT上显示疾病活动，导致预期注射（占9.3%）。83%的真实阳性警报是由视网膜静脉阻塞（RVO）的眼睛产生的。发生了11例假阴性事件（AMD 6例（55%），RVO 4例（36%），近视MNV 1例（9%））。虽然出现了7次假阳性警报，但未发生原发性渗出。检测OCT复发的警报的总体敏感性为35.3% (95% CI [12.6；58])，特异性为93% (95% CI [90.3；95.8])，阳性预测值为20.7% (95% CI [6；35.7])，阴性预测值为96.5% (95% CI [94.5；98.6])。RVO的敏感性更高(55.6% (95% CI [26.7；81.1])高于AMD (14.3% (95% CI [2.6；51.3])。结论在奥德莱特的现实实验中，一半的患者在初始处方后使用了该应用程序。糖尿病患者的参与率较低。尽管存在大量假阳性，但奥德莱特®允许约10%的队列接受早期玻璃体内注射。AMD二级预防的敏感性较低，而RVO患者的敏感性较好。在初级预防中额外使用可能值得怀疑。

{"title":"Real-life evaluation of the home vision monitoring application Odysight® in primary and secondary prevention of exudative maculopathies","authors":"Auberie Bonjean , Mathieu Lehmann , Laura Moyal , Pascale Massin , Bénédicte Dupas","doi":"10.1016/j.jfop.2025.100166","DOIUrl":"10.1016/j.jfop.2025.100166","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the performance of the Odysight® self-monitoring tool for primary and secondary prevention of exudative maculopathies.</div></div><div><h3>Methods</h3><div>A one-year retrospective evaluation was conducted in a private practice. An alert was considered significant (SA) when patient was symptomatic, and non significant (NSA) when the patient was asymptomatic and the VA drop was refuted by an additional test carried out the next day.</div></div><div><h3>Results</h3><div>Of the 92 patients who received a prescription, 44 (48%) downloaded and used the application and were analyzed. At the end of the year, there were 24 (55.8%) active patients. 29 alerts were generated, 13 were considered as NSA, and no anticipated appointment was given. The remaining 16 alerts were SA, 6 (21%) of them were true positive, i.e, revelealed a disease activity on OCT, leading to anticipated injection (representing 9.3% of the patients). 83% of the true positive alerts were generated by eyes with retinal vein occlusion (RVO). Eleven false negative events occurred (6 (55%) for AMD, 4 (36%) for RVO, 1 (9%) for myopic MNV). No primary exudation occured, although 7 false positive alerts were generated. The overall sensitivity of alerts for detecting OCT recurrence was 35.3% (95% CI [12.6; 58]), specificity was 93% (95% CI [90.3; 95.8]), positive predictive value was 20.7% (95% CI [6; 35.7]), and negative predictive value was 96.5% (95% CI [94.5; 98.6]). Sensitivity was higher for RVO (55.6% (95% CI [26.7; 81.1]) than for AMD (14.3% (95% CI [2.6; 51.3]).</div></div><div><h3>Conclusion</h3><div>In this real-life experimentation of Odysight, half of the patients used the application after initial prescription. Participation was low among diabetics. Odysight® allowed about 10% of the cohort to receive earlier intravitreal injection, albeit with a high number of false positives. Sensitivity was low in secondary prevention for AMD, and better for patients with RVO. Additional use in primary prevention may be questionable.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"10 ","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitreous hemorrhage complicating toxoplasmic retinochoroiditis in a child: Case report 儿童视网膜脉络膜炎合并玻璃体出血1例

JFO Open Ophthalmology

Pub Date : 2025-06-01 Epub Date: 2025-03-12 DOI: 10.1016/j.jfop.2025.100161

Mahjoub Ahmed , Nesrine Zaafrane , Marouane Harrath , Ilhem Sellem , Mohamed Mahmoudi , Skander Soudani , Amira Atig , Mohamed Ghorbel , Nadia Ben Abdesslem

引用次数: 0

Multimodal imaging of morning glory disc anomaly: Report of two cases 牵牛花椎间盘异常的多模态成像：附2例报告

JFO Open Ophthalmology

Pub Date : 2025-06-01 Epub Date: 2025-05-17 DOI: 10.1016/j.jfop.2025.100167

Ahmed Mahjoub , Chaima Mefteh , Ilhem Sellem , Nesrine Zaafrane , Sarra El Mansouri , Skander Soudani , Aymen Mabrouk , Amira Atig , Mohamed Ghorbel , Nadia Ben Abdesslem

引用次数: 0

Acquired lens coloboma following iridectomy 虹膜切除术后获得性晶状体胶质瘤

JFO Open Ophthalmology

Pub Date : 2025-06-01 Epub Date: 2024-08-28 DOI: 10.1016/j.jfop.2024.100128

Arnav Panigrahi, Shikha Gupta, Viney Gupta

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JFO Open Ophthalmology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀